Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0XJLTL)
| ADC Name |
JNJ-95298177
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
JNJ-95298177; ARX517; JNJ-8177
Click to Show/Hide
|
|||||
| Organization |
Ambrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-PSMA IgG1k mAb
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Amberstatin 269 (AS269)
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Oxime-PEG3
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
amberstatin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Prostate cancer |
1 Trials
|